Colorado Patent of the Month – July 2023

Plasma medicine is an emerging field that combines plasma physics, life sciences and clinical medicine. In recent years, plasma medicine has witnessed significant advancements in the treatment of biological disorders, including infections, wounds, and even cancer. One company at the forefront of this research is Symbios Technologies, Inc.. The company has developed a groundbreaking method for treating pancreatic cancer using electrochemical plasma activated aqueous chemotherapeutics – with no toxic effect on healthy cells.

Their method utilizes a diluted sodium chloride solution which is circulated through a high-density plasma reactor, where it is exposed to an atmospheric pressure air plasma discharge for a selected period of time. The plasma activation process alters the solution’s pH, creating a plasma activated solution. To make it suitable for therapeutic use, a base is added to adjust the pH to 7.4±0.1, resulting in a physiological solution. Sodium chloride is further added to achieve a chosen quantity, making it an isotonic solution.

The key breakthrough lies in the ability of this isotonic solution to selectively target and inhibit the proliferation of pancreatic cancer cells, while leaving normal cells unaffected. This selectivity is a major advantage over traditional chemotherapy drugs that can harm healthy cells, leading to severe side effects. The electrochemical plasma activated aqueous chemotherapeutics solution demonstrates superior efficacy in reducing pancreatic cancer cell proliferation.

The method offers different administration options depending on the desired approach. It can involve injecting the isotonic solution directly into the pancreas or the tissue surrounding it. Alternatively, intravenous injection may be employed to ensure systemic delivery throughout the body.

Symbios Technologies’ electrochemical plasma activated aqueous chemotherapeutics represent a promising development in cancer treatment. The company’s method harnesses the power of non-thermal plasma to generate activated species capable of selectively inhibiting pancreatic cancer cell proliferation. By minimizing cytotoxic effects on healthy cells, this innovative approach holds great potential for improving oncological outcomes and reducing the adverse effects associated with traditional chemotherapy.

Through ongoing research and clinical trials, Symbios Technologies continues to push the boundaries of Plasma Medicine, striving to provide effective and safe treatments for pancreatic cancer and other diseases. Their groundbreaking method showcases the immense potential of plasma-based therapies in revolutionizing the field of cancer treatment, offering hope to patients and healthcare professionals alike.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at or contact your usual Swanson Reed representative.

Recent Posts